XML 35 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Share Option Plans and ESPP (Tables)
 3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]  
Schedule of Stock Option Plans
A summary of the status of the Company’s option plans as of March 31, 2021 and changes during the period then ended is presented below:
Three months ended March 31, 2021
Unaudited
Number
of options		Weighted
average
exercise
price
Outstanding at beginning of year9,220,326 $26.21 
Granted375,689 153.09 
Exercised(404,591)19.36 
Forfeited and canceled(20,911)62.86 
Outstanding as of March 31, 20219,170,513 $31.63 
Exercisable options5,344,848 $18.59 
Schedule of RSUs and PSUs A summary of the status of the Company’s RSUs and PSUs as of March 31, 2021 and changes during the period then ended is presented below.
Three months ended March 31, 2021
Unaudited
Number
of RSU/PSUs		Weighted
average
grant date fair value
Unvested at beginning of year4,466,151 $54.06 
Granted538,908 139.43 
Vested(448,593)48.38 
Forfeited and cancelled(12,262)75.05 
Unvested as of March 31, 2021 (1)4,544,204 64.69 

(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones which are not probable, as of March 31, 2021, in accordance with ASC 718 as follows:
 March 31, 2021
Number of
PSUs		Fair value at grant date per PSUTotal fair value at gtant date
2,703,852 $48.16 $130,218 
216,226 69.37 15,000 
35,424 84.68 3,000 
94,813 $114.26 10,833 
3,050,315 $159,050 
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. We assessed fair value using the following underlying assumptions: 
Three months ended March 31,Year ended December 31,
2020
20212020
UnauditedAudited
Stock Option Plans
Expected term (years)
5.86-6.00
6.25
5.50-6.00
Expected volatility60 %54 %
54%-56%
Risk-free interest rate
0.85%-0.88%
0.86 %
0.30%-0.86%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility55 %47 %
47%-66%
Risk-free interest rate0.09 %1.57 %
0.17%-1.57%
Dividend yield0.00 %0.00 %0.00 %
Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2021 and 2020 and the year ended December 31, 2020 was:
Three months ended March 31,Year ended December 31,
2020
20212020
UnauditedAudited
Cost of revenues$733 $590 $2,221 
Research, development and clinical trials5,124 3,394 18,125 
Sales and marketing4,471 3,616 17,672 
General and administrative8,535 8,957 37,703 
Total share-based compensation expense$18,863 $16,557 $75,721